Compare iShares MSCI Hong Kong ETF (EWH) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs GeneDx Holdings Corp — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06 (market cap $1.16B), while GeneDx Holdings Corp trades at $67.82 (market cap $2.02B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and GeneDx Holdings Corp for 19 Days on average.
| EWH | WGS | |
|---|---|---|
Market Cap | $1.16B | $2.02B |
Volume | 3,176,523 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $167.51 |
52-Week Low | $20.66 | $34.51 |
Typical Hold Time | 61 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 2.13% in the last 24 hours. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $21. Recent news highlights volatility in the Hang Seng Index, driven by Federal Reserve decisions and geopolitical tensions. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The ETF faces headwinds from Hong Kong market weakness and institutional selling, but oversold conditions per RSI may offer tactical opportunities. Risks include ongoing U.S.-China tensions and economic pressures. Investors should weigh exposure to Hong Kong equities against broader market risks.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
